Labcorp Holdings Inc
LH251.810USD
-2.860-1.12%
Handelsschluss 01/09, 16:00（ET）Kurse um 15 Minuten verzögert
20.90BMarktkapitalisierung
24.56KGV TTM
mehr Informationen über Labcorp Holdings Inc Unternehmen
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Labcorp Holdings Inc Informationen
BörsenkürzelLH
Name des UnternehmensLabcorp Holdings Inc
IPO-datumApr 24, 1991
CEOSchechter (Adam H)
Anzahl der mitarbeiter70000
WertpapierartOrdinary Share
GeschäftsjahresendeApr 24
Addresse358 S Main St
StadtBURLINGTON
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl27215
Telefon13362291127
Websitehttps://www.labcorp.com/
BörsenkürzelLH
IPO-datumApr 24, 1991
CEOSchechter (Adam H)
Führungskräfte von Labcorp Holdings Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-5745.00%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-2000.00%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+1972.00%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-4000.00%
Ms. Amy B. Summy
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
5.30K
+757.00%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
4.96K
--
Mr. Akinbolade Oyegunwa
Mr. Akinbolade Oyegunwa
Executive Vice President and Chief Information and Technology Officer
Executive Vice President and Chief Information and Technology Officer
3.73K
+263.00%
Ms. Megan D. Bailey
Ms. Megan D. Bailey
Executive Vice President and President - Central Laboratories and International
Executive Vice President and President - Central Laboratories and International
3.59K
+191.00%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-5745.00%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-2000.00%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+1972.00%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-4000.00%
Umsatzaufteilung
Währung: USDAktualisiert: Wed, Mar 12
Währung: USDAktualisiert: Wed, Mar 12
FY2021
FY2020
FY2019
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
Northern America
13.09B
81.22%
Europe
2.05B
12.72%
Other Countries
976.40M
6.06%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
Andere
72.54%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
Andere
72.54%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
50.39%
Investment Advisor/Hedge Fund
38.82%
Research Firm
2.40%
Pension Fund
1.76%
Hedge Fund
1.61%
Bank and Trust
1.56%
Sovereign Wealth Fund
1.25%
Individual Investor
0.36%
Family Office
0.26%
Andere
1.59%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
1803
80.86M
97.54%
-4.56M
2025Q3
1802
83.09M
100.23%
+765.81K
2025Q2
1825
81.46M
98.03%
-5.42M
2025Q1
1872
81.69M
97.58%
-5.17M
2024Q4
1872
81.10M
96.90%
-5.32M
2024Q3
1856
80.09M
95.55%
-6.82M
2024Q2
1876
81.29M
96.43%
-7.49M
2024Q1
1904
82.39M
97.73%
-8.65M
2023Q4
1947
83.11M
99.02%
-9.76M
2023Q3
1930
84.34M
99.29%
-7.18M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
9.78M
11.79%
-66.55K
-0.68%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.39M
5.3%
-10.58K
-0.24%
Sep 30, 2025
State Street Investment Management (US)
3.83M
4.62%
-31.13K
-0.81%
Sep 30, 2025
Victory Capital Management Inc.
2.64M
3.18%
+440.22K
+20.04%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.12M
2.56%
+9.78K
+0.46%
Sep 30, 2025
Wellington Management Company, LLP
2.11M
2.54%
+289.03K
+15.91%
Sep 30, 2025
Allspring Global Investments, LLC
2.00M
2.41%
-4.51K
-0.23%
Sep 30, 2025
Select Equity Group, L.P.
1.84M
2.22%
-295.76K
-13.87%
Sep 30, 2025
Diamond Hill Capital Management Inc.
1.64M
1.98%
-181.26K
-9.94%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.25M
1.5%
-41.66K
-3.23%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares U.S. Healthcare Providers ETF
3.32%
Knowledge Leaders Developed World ETF
2.73%
Thrivent Small-Mid Cap ESG ETF
2.26%
State Street SPDR S&P Health Care Services ETF
1.9%
Schwab Ariel Opportunities ETF
1.62%
Brandes US Value ETF
1.56%
Invesco S&P 500 Equal Weight Health Care ETF
1.52%
Madison Covered Call ETF
1.49%
Nuveen ESG Mid-Cap Value ETF
1.4%
Franklin Genomic Advancements ETF
1.25%
Mehr Anzeigen
iShares U.S. Healthcare Providers ETF
Anteil3.32%
Knowledge Leaders Developed World ETF
Anteil2.73%
Thrivent Small-Mid Cap ESG ETF
Anteil2.26%
State Street SPDR S&P Health Care Services ETF
Anteil1.9%
Schwab Ariel Opportunities ETF
Anteil1.62%
Brandes US Value ETF
Anteil1.56%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.52%
Madison Covered Call ETF
Anteil1.49%
Nuveen ESG Mid-Cap Value ETF
Anteil1.4%
Franklin Genomic Advancements ETF
Anteil1.25%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
692.30M
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Oct 08, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 11, 2025 going ex on Nov 26, 2025
Nov 26, 2025
Dec 11, 2025
Nov 26, 2025
Jul 10, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 11, 2025 going ex on Aug 28, 2025
Aug 28, 2025
Sep 11, 2025
Aug 28, 2025
Apr 10, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 11, 2025 going ex on May 29, 2025
May 29, 2025
Jun 11, 2025
May 29, 2025
Jan 09, 2025
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
Feb 27, 2025
Mar 12, 2025
Feb 27, 2025
Oct 10, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 13, 2024
Nov 26, 2024
Jul 25, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
Aug 29, 2024
Sep 13, 2024
Aug 29, 2024
Apr 11, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
May 28, 2024
Jun 12, 2024
May 24, 2024
Jan 12, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
Feb 27, 2024
Mar 13, 2024
Feb 26, 2024
Oct 12, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
Nov 08, 2023
Dec 12, 2023
Nov 07, 2023
Jul 13, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
Aug 08, 2023
Sep 08, 2023
Aug 07, 2023
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Labcorp Holdings Inc?
Die fünf größten Anteilseigner von Labcorp Holdings Inc sind:
The Vanguard Group, Inc. hält 9.78M Aktien, was 11.79% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 4.39M Aktien, was 5.30% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 3.83M Aktien, was 4.62% der Gesamtaktien entspricht.
Victory Capital Management Inc. hält 2.64M Aktien, was 3.18% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 2.12M Aktien, was 2.56% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 9.78M Aktien, was 11.79% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 4.39M Aktien, was 5.30% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 3.83M Aktien, was 4.62% der Gesamtaktien entspricht.
Victory Capital Management Inc. hält 2.64M Aktien, was 3.18% der Gesamtaktien entspricht.
Geode Capital Management, L.L.C. hält 2.12M Aktien, was 2.56% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Labcorp Holdings Inc?
Die drei wichtigsten Anteilseigner-Typen von Labcorp Holdings Inc sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Wie viele Institutionen halten Anteile an Labcorp Holdings Inc (LH)?
Mit Stand vom 2025Q4 halten 1803 Institutionen Anteile an Labcorp Holdings Inc, mit einem Gesamtmarktwert von etwa 80.86M, was 97.54% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -2.70% gestiegen.
Was ist die größte Einnahmequelle von Labcorp Holdings Inc?
Am FY2021 erzielte das Geschäft mit -- für Labcorp Holdings Inc den höchsten Umsatz in Höhe von --, was --% des Gesamtumsatzes entspricht.
